{Reference Type}: Journal Article
{Title}: COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.
{Author}: Azad N;Hu Z;Sahin I;Iyer R;Aranha O;Hochster H;Pathak P;Paulson AS;Kalyan A;Liao CY;Tran N;Kelley RK;Heestand G;Cosgrove D;El-Khoueiry A;Borad M;Gabrail NY;Majeed U;Du L;Kamath S;Shumway N;Shroff R;Goyal L;Rosales M;Javle M;
{Journal}: Future Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 4
{Factor}: 3.674
{DOI}: 10.1080/14796694.2024.2351351
{Abstract}: Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in patients with advanced cancers as both a monotherapy and in combination with chemotherapy. In a phase II study of patients with advanced biliary tract cancer who had received one or two prior therapies, CTX-009 with paclitaxel demonstrated a 37.5% overall response rate (ORR). Described here is the design of and rationale for COMPANION-002, a randomized phase II/III study, which will evaluate the safety and efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone as second-line treatment for patients with advanced biliary tract cancer. The primary end point is ORR, and crossover is allowed.Clinical Trial Registration: NCT05506943 (ClinicalTrials.gov).<BR>Looking for new options for patients with advanced biliary tract cancer? Explore COMPANION-002, Compass Therapeutics’ phase II/III study of CTX-009 + paclitaxel as a second line treatment.#CMPX #biotech #healthcare #rarecancer.